Tracking the clonal origin of lethal prostate cancer

Michael C. Haffner,1 Timothy Mosbruger,1 David M. Esopi,1 Helen Fedor,2 Christopher M. Heaphy,2 David A. Walker,1 Nkosi Adejola,1 Meltem Gürel,1 Jessica Hicks,2 Alan K. Meeker,1,2,3 Marc K. Halushka,2 Jonathan W. Simons,4 William B. Isaacs,1,2,3 Angelo M. De Marzo,1,2,3 William G. Nelson,1,2,3 and Srinivasan Yegnasubramanian1

1Sidney Kimmel Comprehensive Cancer Center, 2Department of Pathology, and 3Brady Urological Institute, Johns Hopkins School of Medicine, Baltimore, Maryland, USA. 4Prostate Cancer Foundation, Santa Monica, California, USA.

Recent controversies surrounding prostate cancer overtreatment emphasize the critical need to delineate the molecular features associated with progression to lethal metastatic disease. Here, we have used whole-genome sequencing and molecular pathological analyses to characterize the lethal cell clone in a patient who died of prostate cancer. We tracked the evolution of the lethal cell clone from the primary cancer to metastases through samples collected during disease progression and at the time of death. Surprisingly, these analyses revealed that the lethal clone arose from a small, relatively low-grade cancer focus in the primary tumor, and not from the bulk, higher-grade primary cancer or from a lymph node metastasis resected at prostatectomy. Despite being limited to one case, these findings highlight the potential importance of developing and implementing molecular prognostic and predictive markers, such as alterations of tumor suppressor proteins PTEN or p53, to augment current pathological evaluation and delineate clonal heterogeneity. Furthermore, this case illustrates the potential need in precision medicine to longitudinally sample metastatic lesions to capture the evolving constellation of alterations during progression. Similar comprehensive studies of additional prostate cancer cases are warranted to understand the extent to which these issues may challenge prostate cancer clinical management.

Introduction
Prostate cancer is the most frequently diagnosed malignancy and second leading cause of cancer-specific deaths in men in the United States (1). Clinically, prostate cancer is highly heterogeneous; manifestations vary from indolent localized tumors to widespread metastases. Given recent controversies surrounding overtreatment of prostate cancer, there is a critical need to understand the features of the primary tumor that are associated with progression to lethal disease (2, 3).

Primary prostate cancers often harbor multiple morphologically and clonally distinct tumor foci (4–6). Despite the multifocal and multiclonal heterogeneity of primary prostate tumors, most distant metastases from different anatomic sites in the same patient share the majority of genetic alterations, which suggests a monoclonal origin of lethal metastatic cells (7, 8). Therefore, identifying the characteristics of the primary cancer lesion that ultimately can give rise to the lethal metastatic cell clone is of great interest. Studying the full spectrum of prostate cancer presentation and progression would require longitudinal, integrated analysis of the primary cancer and matched metachronous metastases sampled during disease progression and at death (9). Perhaps due to the protracted natural history of prostate cancer, such a study has not been conducted thus far.

Here we present the case of a man with lethal metastatic prostate cancer for whom, through longitudinal sampling and comprehensive genomic and pathological analysis, we identified the constellation of genomic alterations that characterized the lethal metastatic cell clone and traced its origin back to a specific lesion in the primary cancer.

Results and Discussion
The subject was diagnosed with prostate adenocarcinoma at age 47 years. His entire primary tumor and a single involved lymph node metastasis was initially removed by radical prostatectomy, but an elevated PSA level 5 years after surgery suggested systemic disease and prompted therapy with an investigational prostate cancer vaccine (GVAX; ref. 10), androgen ablation, systemic chemotherapy, and localized radiation (Supplemental Information and Supplemental Figure 1; supplemental material available online with this article; doi:10.1172/JCI70354DS1). Despite these interventions, 17 years after initial presentation, the patient succumbed to overwhelming castrate-resistant prostate cancer at 64 years of age. After death, tissues from 7 metastatic sites were procured by rapid autopsy. To define the genetic features of the cell clone that gave rise to the lethal tumor burden, we performed whole-genome sequencing on 3 anatomically distinct autopsy metastases — M5 (liver), M38 (perigastric lymph node), and M40 (lung) — and germline DNA, with average sequencing coverage exceeding 50× (Supplemental Table 1 and ref. 11). We identified 85 coding mutations and 226 structural rearrangements (19 [8.4%] interchromosomal and 207 [91.6%] intrachromosomal) that were common to all 3 metastatic sites (Figure 1 and Supplemental Tables 2 and 3). None of the metastases harbored rearrangements involving TMPRSS2, ERG, or other ETS transcription factors. All 3 metastases also shared widespread copy number alterations (Supplemental Figure 2 and Supplemental Table 4). A >60-fold amplification of the AR locus was present in all distant hormone-refractory metastases (Supplemental Figure 3 and Supplemental Table 4). Although there was some genetic heterogeneity among...
metastases (Supplemental Figure 2), the high number of shared alterations indicated a monoclonal origin.

Among the index alterations characterizing the genetic landscape of the lethal metastatic cell clone were mutations in PTEN (4-bp frameshifting deletion in exon 7 with loss of heterozygosity [LOH]), TP53 (R248Q, LOH), and SPOP (F133L), all known to be recurrent targets of mutation in advanced prostate cancer (12–14). These alterations were confirmed by Sanger sequencing in all 7 autopsy metastases (Figure 2A and Supplemental Figure 4). Immunohistochemical analysis showed that the PTEN and TP53
mutations produced loss of PTEN staining and nuclear accumulation of p53, as expected (Figure 2, B–D, and Supplemental Figure 5). Thus, from a molecular taxonomy perspective, this case belongs to a prostate cancer subtype characterized by the absence of ETS rearrangement of p53, as expected (Figure 2, B–D, and Supplemental Figure 5). (E) The genomic inversion within the ATRX gene was associated with strong nuclear accumulation of telomeric sequence, consistent with ALT.

Interestingly, we identified only a single small (2.2 mm × 1.3 mm) lesion (referred to herein as P1), composed solely of Gleason pattern 3 tumor glands, that was devoid of PTEN staining in the primary cancer (Figure 3A and Supplemental Figures 7 and 8). Targeted sequencing of DNA recovered from microdissected cells from the PTEN-negative P1 revealed a 4-bp deletion in PTEN identical to the one present in the autopsy metastases (Figure 3B and Supplemental Figure 9). In contrast, this PTEN mutation was not present in DNA from 8 surrounding higher-grade lesions (P2–P9). Furthermore, the SPOP mutation was present in P1 as well as in P6 and P8, but not in any other sampled lesions from the primary cancer (Figure 3B and Supplemental Figure 9). Additionally, we detected the TP53 mutation in a subset of alleles from P1, but not from any other sampled region of the primary tumor (Figure 3B and Supplemental Figure 9), which suggests the emergence of a progressive subclone with TP53 mutation within P1. Together, these observations demonstrate a clonal relationship between P1 and the autopsy metastases and suggest that the lethal metastatic clone arose from P1 (a small, well-differentiated Gleason pattern 3 primary lesion), not from the prevalent Gleason pattern 4 cancer. This finding is particularly surprising since isolated Gleason pattern 3 lesions have shown no evidence of metastatic potential or progression to lethality (16, 17). Therefore, a Gleason pattern 3 lesion in close proximity to higher-grade lesions could have biological properties different than those of isolated Gleason pattern 3 lesions. Furthermore, because P1 was the only part of the primary cancer containing cells with index mutations in PTEN and TP53, which have previously been associated with aggressive disease (18–20), comprehensive evaluation of PTEN and TP53 status could be useful for identifying lesions in the primary tumor that are more likely to progress. Overall, these data suggest that P1 initially seeded a micrometastasis that escaped initial therapy and gave rise to all subsequent metastases, either directly or indirectly, through sequential dissemination from metastasis to metastasis.

Despite the similarities between P1 and the autopsy metastases, we observed evidence for additional clonal evolution. None of the primary lesions, including P1, harbored the ATRX rearrangement or AR amplification (Figure 3B and Supplemental Figures 3 and 6),
which suggests that generation and selection of a cell clone harboring these alterations was a later event, likely arising after androgen deprivation therapy (Supplemental Figure 3). Furthermore, a lung lesion that was biopsied 16 months prior to autopsy showed no evidence for ALT and ATRX alterations, despite having the PTEN, TP53, and SPOP mutations, amplification of AR, and high proliferation rates (Ki-67 index, >25%) similar to those of the autopsy metastases (Figure 3 and Supplemental Figures 9 and 10). This indicates that the ATRX alteration may represent a very late event in this case.

Interestingly, the lymph node metastasis resected at radical prostatectomy did not harbor PTEN, SPOP, TP53, or ATRX mutations (Supplemental Figures 9 and 10), suggestive of an independent clonal/subclonal origin of this lesion. This finding provides proof-of-concept of the potential utility of repeated longitudinal evaluation of lesions during clinical management in order to effectively target the evolving spectrum of molecular alterations during progression (21–24). These observations also suggest that multiple tumor clones may arise, regress, and evolve during disease progression and treatment, similar to what has been observed for other cancers (21–24). However, the degree of clonal heterogeneity within the primary tumor and between the primary tumor and distant metastases may vary significantly in different tumor

**Figure 3**

Molecular and pathological findings in the primary tumor and their clonal relationship to the distant metastases. (A) PTEN staining in a cross-section of the primary prostatectomy specimen (LA, left anterior; RA, right anterior; LP, left posterior; RP, right posterior). Individual tumor areas that were further analyzed are indicated; green dotted outline denotes areas containing tumor glands. P1 was the only lesion in the primary tumor devoid of PTEN staining in neoplastic cells. The adjacent P2 stained positive for PTEN, and in this regard was representative of the bulk tumor outside P1. Arrows indicate tumor cells. Note that the surrounding normal stroma showed strong immunoreactivity for PTEN. Original magnification, ×2 (top); ×40 (bottom). Scale bar: 10 mm. (B) Summary of the analyzed consensus genomic alterations in the primary tumor and metastases. The presence and absence of the consensus mutations are denoted by blue and gray, respectively. (C) Proposed model of disease progression in this index case, based on sequencing and molecular pathological analyses. Phylogenetic relationships of distant metastases were calculated based on structural rearrangements.
types (22, 24, 25). Additionally, the various therapies, including the experimental GVAX vaccine, aggressive androgen ablation, or the other interventions, may have substantially affected the clonal evolution of the disease in this case (Figure 3C). For instance, inactivation of PTEN has been associated with resistance to androgen ablation (26), which might explain the clonal selection of the PTEN mutated cell clone during hormonal therapy in this case.

A limitation of this study is that, since this is the first prostate cancer case for which it was possible to carry out such detailed longitudinal characterization of the lethal cell clone from the primary cancer to distant metastases, the extent to which these findings are generalizable is unclear. Nonetheless, this case is in many regards highly typical of prostate cancer in a clinical and molecular sense, which may indicate that these findings could be more generalizable. Future studies with additional cases will be needed to test this notion. Another limitation is that microdissection of the primary tumor lesions from archival FFPE blocks that were approximately 2 decades old yielded insufficient high-quality DNA for genome-wide analyses. This limited our ability to comprehensively delineate potential subclonal relationships between P1 and other lesions in the primary cancer and metastases. For example, such analyses could have allowed delineation of a possible subclonal relationship among P1, P6, and P8, all of which harbored the recurrent SPOP mutations.

Broadly, our present study documents the potential of integrated genomic and histopathological approaches to characterize tumor heterogeneity. It also provides proof-of-concept of the potential importance of molecular staging and grading strategies, in conjunction with existing pathological criteria, to accurately inform clinical decision making in precision medicine. Using such longitudinal evaluation, future efforts to examine clonal evolution in prostate cancer progression can help us understand whether this index case represents a rare outlier or a common manifestation of the disease.

**Methods**

7 distant metastases from distinct anatomic sites were procured by rapid autopsy. DNA of 3 metastases and normal constitutional DNA was subjected to massively parallel whole-genome sequencing by Complete Genomics (11). Archival FFPE samples of the primary tumor, a lymph node metastasis resected at radical prostatectomy, and a biopsy of the lung metastasis were enriched for tumor cells by microdissection, and extracted DNA was analyzed by PCR and Sanger sequencing. Immunohistochemistry for PTEN, p53, and ATRX and telomere-specific FISH were performed as described previously (15, 20). See Supplemental Methods and Supplemental Table 5 for details.

**Study approval.** The Johns Hopkins Institutional Review Board approved the study, and written informed consent was obtained.

**Acknowledgments**

This manuscript is dedicated to the gentleman and his family, whose commitment to advancing prostate cancer research and generous tissue donation made this study possible. This study was supported by funding from the NIH/NCI (P50CA058236, R01CA070196); DOD (PC073533/W81XWH-08-1-0049); The Prostate Cancer Foundation David Mazzone Challenge award and Creativity award; The V Foundation Martin D. Abeloff V Scholar Award (to S. Yegnasubramanian); The Cleveland Foundation Ellen B. Masenheimer Fellowship (to S. Yegnasubramanian); and the Commonwealth Foundation for Cancer Research. Alison Mass-Bommarito, Sal Bommarito, and the Irving Hansen Foundation provided additional generous philanthropic support. M.C. Haffner is supported by the Richard and Ellen Sandler Young Investigator Award from the Prostate Cancer Foundation. This work is supported by the Department of Defense Prostate Cancer Research Program, DOD award no. W81XWH-10-2-0056 and W81XWH-10-2-0046 PCRP Prostate Cancer Biorepository Network (PCBN).

Received for publication April 9, 2013, and accepted in revised form August 12, 2013.

Address correspondence to: Srinivasan Yegnasubramanian, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Kisch Cancer Research Bldg., Rm. 145, 1550 Orleans St., Baltimore, Maryland 21231, USA. Phone: 410.502.3425; Fax: 410.502.9817; E-mail: syegnasu@jhmi.edu.

4. Arora R, Koch MO, Eble JN, Ulbright TM, Li L, Bommarito, and the Irving Hansen Foundation provided additional generous philanthropic support. M.C. Haffner is supported by the Richard and Ellen Sandler Young Investigator Award from the Prostate Cancer Foundation. This work is supported by the Department of Defense Prostate Cancer Research Program, DOD award no. W81XWH-10-2-0056 and W81XWH-10-2-0046 PCRP Prostate Cancer Biorepository Network (PCBN).

4. Arora R, Koch MO, Eble JN, Ulbright TM, Li L, Bommarito, and the Irving Hansen Foundation provided additional generous philanthropic support. M.C. Haffner is supported by the Richard and Ellen Sandler Young Investigator Award from the Prostate Cancer Foundation. This work is supported by the Department of Defense Prostate Cancer Research Program, DOD award no. W81XWH-10-2-0056 and W81XWH-10-2-0046 PCRP Prostate Cancer Biorepository Network (PCBN).

Received for publication April 9, 2013, and accepted in revised form August 12, 2013.

Address correspondence to: Srinivasan Yegnasubramanian, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Kisch Cancer Research Bldg., Rm. 145, 1550 Orleans St., Baltimore, Maryland 21231, USA. Phone: 410.502.3425; Fax: 410.502.9817; E-mail: syegnasu@jhmi.edu.

4. Arora R, Koch MO, Eble JN, Ulbright TM, Li L, Bommarito, and the Irving Hansen Foundation provided additional generous philanthropic support. M.C. Haffner is supported by the Richard and Ellen Sandler Young Investigator Award from the Prostate Cancer Foundation. This work is supported by the Department of Defense Prostate Cancer Research Program, DOD award no. W81XWH-10-2-0056 and W81XWH-10-2-0046 PCRP Prostate Cancer Biorepository Network (PCBN).

4. Arora R, Koch MO, Eble JN, Ulbright TM, Li L, Bommarito, and the Irving Hansen Foundation provided additional generous philanthropic support. M.C. Haffner is supported by the Richard and Ellen Sandler Young Investigator Award from the Prostate Cancer Foundation. This work is supported by the Department of Defense Prostate Cancer Research Program, DOD award no. W81XWH-10-2-0056 and W81XWH-10-2-0046 PCRP Prostate Cancer Biorepository Network (PCBN).

Received for publication April 9, 2013, and accepted in revised form August 12, 2013.

Address correspondence to: Srinivasan Yegnasubramanian, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Kisch Cancer Research Bldg., Rm. 145, 1550 Orleans St., Baltimore, Maryland 21231, USA. Phone: 410.502.3425; Fax: 410.502.9817; E-mail: syegnasu@jhmi.edu.